S-y AQ4N (l,4-bLs-q25ddimthyai oo y}amin5dydroxy-anthrane-9,10-dione) is a novel alkylaminoanthraquinone N-oxide which, on reducin, forms a stable DNA affinic cytotoxi compound AQ4. The The failure to cure tumours with radiotherapy and chemotherapy has been attributed in part to the presence of treatment-resistant subpopulations of hypoxic tumour cells (Bush et at., 1978). Bioreductive agents provide a novel approach to this problem: reduction of the prodrug within a hypoxic cell to produce a cytotoxic metabolite should selectively target this sub population within tumours. Since normal tissus contain few, if any, poorly oxygenated cells, systemic reductive activation and its attendant toxicity should be minimal. Several classe of bioreductive agents have been described, icluding the nitroimidazoles, benzotriazene di-N-oXides and mitosenes (Workman, 1992) . Using a different class of compounds, i.e. the anthraquinones, we have developed a novel alkylamnoanthraquinone N-oxide, AQ4N (1,4-bis-{[2-(di-methylamino-N-oxide)ethylarmino}5,8-dihydroxyanthracene-9,10-ione), which is susceptible to reduction under hypoxic conditions (Patterson, 1993) . AQ4N is a weak DNA-binding agent and weak topoisomerase H inhibitor, critically, the electrically neutral N-oxide function prevents stable binding to the DNA helix (Patterson, 1993) . In contrast, the reduction product of AQ4N, i.e. AQ4 (1,4-bis-{[2-(dimethylamino) ethylnamino}5,8-dihydroxyanthracene-9,10-dione) (Figure 1) , is a cationic compound with high affinity for DNA. Interaction of AQ4 with DNA is facilitated by the planar, eletrondeficient antraquinone chromophore intercalating between adjcent DNA bases. Tlis complex is further stabiised by electrostatic interactions and hydrogen bonding with the deoxyribose phosphate backbone, as has been observed for similar anthraquinones (Denny and Wakelin, 1990 al., 1992). This will allow metabolism of the drug in cells which will contribute, when the hypoxic stimulus is removed, to the main growth frction within the tumour. Secondly, the drug can be combined with an agent which is selectively toxic to well-oxygenated cells to evahuate the effect of targeting the two subpopulations of cells (Brown and Lemmon, 1991; Grau and Overgaard, 1991) . We have used both these approaches to study the effect of AQ4N on tumour growth in vivo. Firstly, we tested the anti-tumour effect of AQ4N when combined with hypobaric hypoxia. Following this we combined AQ4N with radiation as both single and fractionated doses.
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The failure to cure tumours with radiotherapy and chemotherapy has been attributed in part to the presence of treatment-resistant subpopulations of hypoxic tumour cells (Bush et at., 1978) . Bioreductive agents provide a novel approach to this problem: reduction of the prodrug within a hypoxic cell to produce a cytotoxic metabolite should selectively target this sub population within tumours. Since normal tissus contain few, if any, poorly oxygenated cells, systemic reductive activation and its attendant toxicity should be minimal.
Several classe of bioreductive agents have been described, icluding the nitroimidazoles, benzotriazene di-N-oXides and mitosenes (Workman, 1992) . Using a different class of compounds, i.e. the anthraquinones, we have developed a novel alkylamnoanthraquinone N-oxide, AQ4N (1,4-bis-{[2-(di- methylamino-N-oxide)ethylarmino}5,8-dihydroxyanthracene-9,10-ione), which is susceptible to reduction under hypoxic conditions (Patterson, 1993) . AQ4N is a weak DNA-binding agent and weak topoisomerase H inhibitor, critically, the electrically neutral N-oxide function prevents stable binding to the DNA helix (Patterson, 1993) . In contrast, the reduction product of AQ4N, i.e. AQ4 (1,4-bis-{[2-(dimethylamino) ethylnamino}5,8-dihydroxyanthracene-9,10-dione) (Figure 1) , is a cationic compound with high affinity for DNA. Interaction of AQ4 with DNA is facilitated by the planar, eletrondeficient antraquinone chromophore intercalating between adjcent DNA bases. Tlis complex is further stabiised by electrostatic interactions and hydrogen bonding with the deoxyribose phosphate backbone, as has been observed for similar anthraquinones (Denny and Wakelin, 1990) . The tiking level of DNA binding of AQ4 is similar in magnitude to that of its suctural analogue, mitoxantrone, a chemotherapeutic agent which is clnially proven and widely used in oncology. In addition, like mitoxantrone, AQ4 has been shown to inhibit topoisomerase II (Patterson, 1993 (Workman and Stratford, 1993) . Firstly the tumour may be made more hypoxic (Bremner et al., 1990; McAleer et al., 1992) . This will allow metabolism of the drug in cells which will contribute, when the hypoxic stimulus is removed, to the main growth frction within the tumour. Secondly, the drug can be combined with an agent which is selectively toxic to well-oxygenated cells to evahuate the effect of targeting the two subpopulations of cells (Brown and Lemmon, 1991; Grau and Overgaard, 1991) . We have used both these approaches to study the effect of AQ4N on tumour growth in vivo. Firstly, we tested the anti-tumour effect of AQ4N when combined with hypobaric hypoxia. Following this we combined AQ4N with radiation as both single and fractionated doses.
Materiak an mth Tumour system
The T50/80 tumour is a poorly differentiated mammary carcinoma which arose in a B6D2FI mouse. Tumour and breeding colonies for mice were obtained from Dr JV Moore, Paterson Laboratory, Christie Hospital, Manchster, UK.
Male B6D2FI mice aged 8-12 weeks were used for all studies, which were carried out in accordance with the UK. Animals (Scientific Procedures) Act 1986. The tumour has been maintained by intadermal passage for up to ten passages and then re-establshed from frozm stock. Tumour brei (0.05 ml) was injected intradermally on the rear dorsum, and treatment was initiated when the tumour dia reached 6.5-7.5 mm (gometric mean of three orthogonal diameters).
Tumour size was measured three times weekly. The time for the tumour to reach double its treatment vohlme (tumour doubling time, TDT) was used as a measure of anti-tumour effiacy. Normally oxygenated mice showed minimal weight loss when given AQ4N up to doses of 400 mg kg-' (0.9 mmol kg-'), although some mice showed a small weight loss in the range 5-10%. There was no evidence of a dose-response relationship. Systemic toxicity was not increased when administration of AQ4N at low doses (up to 50 mg kg-') was followed by induction of hypobaric hypoxia (Figure 2a ). At higher doses (100-200mg kg-') there was appreiabl weight loss (P<0.001), and therefore doses beyond 200mg kg-' were not tested under hypoxic conditions.
We have also studied the systemic toxcity of the bioreductive drugs RSU 1069 and SR 4233 under oxic and hypoxic conditions (Figure 2b and c al., 1992.) enhancement of systemic toxicity in combination with SR 4233, with weight losses of less than 10% only being observed at very low doses (<6mgkg-').
Tumour response: AQ4N with hypobaric hypoxia The anti-tumour effect of AQ4N was assessed by comparing the dose-response curves in mice treated at 1 and 0.55 atmospheres. There was a left shift of the dose-response curve under hypoxic conditions with a DER of 5.1 ( Figure  3) . The values derived previously for SR 4233 and RSU 1069 were 8.8 and 8.5 respectively (McAleer et al., 1992) . The DER results obtained for the three drugs were not significantly different from each other. However, the 95% Twnour response: AQ4N and single dose radiation With single fractions of radiation ranging from 7.5 to 25 Gy there was increasng tumour growth delay (Figure 4 ). For 12 Gy tumour growth delay was 6.93 (s.e. = 0.95). When AQ4N (200 mg kg-') was given alone the tumour growth delay was 3.09 (s.e. = 0.50). In combination these modalities (AQ4N, 200 mg kg'; radiation, 12 Gy) gave a tumour growth delay of approximately 18 days ( Figure 5 ). From the radiation dose-response curve 24 Gy, as a single dose, is required to give an 18 day growth delay. Thus AQ4N reduced by 50% the radiation dose required to give an anti-tumour effect equivalent to that of radiation alone.
In order to maximise the benefit from drug-radiation interactions, it was important to identify the most effective time interval between administration of the two modalities. Initially the drug was administered at a range of times from 90 min before to 60 min after radiation treatment. All of these schedules gave an additive effect with tumour growth delays of approxiimately 18 days (no significant difference). The scheduling experiment was repeated twice using a wider range of time to identify the period over which the additive interaction could be obtained. The interaction was present over a long time period, with the maximal interaction being observed when the drug was administered from 4 days before Drug injection time before/after radiation (h) FJigre 5 Tumour growth delay when AQ4N was administered before or after a single dose of radiation (12 Gy). AQ4N (200mgkg-') was administered at a range of times up to 120h before and 48 h after a single dose of X-irradiation (12 Gy). Tumour growth delay (mean ± s.e.) (6-18 animals per group) is plotted against time of administration. Bars show the tumour growth delay obtained for AQ4N and radiation administered alone (mean ± s.e.). The results are the pooled data from three experiments.
to 6 h after the radiation treatment ( Figure 5 ). An appreciable, but diminishing, effect was still seen when the drug was administered up to 48 h after radiation.
Tumour response: AQ4N with fractionated radiation In clinical practice, radiotherapy is given as a fractionated regimen. Therefore, AQ4N was assessed for its anti-tumour efficacy when administered with 15 Gy given in five daily fractions of 3 Gy (Figure 6 ). Drug was administered in all schedules 30 min before irradiation. When given as a single dose (1 x 200 mg kg-') AQ4N gave a marked enhancement of anti-tumour effect as compared with either modality alone (P<0.01). AQ4N given in two doses (2 x 100 mg kg-') slightly improved the outcome. When AQ4N was given on each day of radiation treatment, but with the same total dose (i.e. 5 x 40 mg kg-'), the anti-tumour effect was significntly increased as compared with the single-dose AQ4N with a fractionated radiation regimen (P<0.01) (Figure 6 ). This combination was as effective as that obtained when single doses of both modalities were combined. AQ4N is a novel alkylaminoanthraquinone N-oxide which shows minimal cytotoxicity to cells even at high concentrations (Patterson et al., 1995) . On exposure to a hypoxic cellular environment the major metabolite formed is AQ4; this is a stable, cytotoxic compound with high affinity for DNA. The hypoxic cytotoxicity of AQ4N to V79 cells is twice that found under normal oxygenation. This can be increased to 100 times when rat liver microsomes are present, suggesting that reductive metabolism of AQ4N requires the presence of specific microsomal enzymes (Patterson, 1993) . It is known that metabolism of AQ4N involves cytochrome P450 (Graham et al., 1993) , which is normally downregulated in vitro (Krupski et al., 1985) . This could explain why only limited reduction of AQ4N is found in vitro. We have recently shown that excised T50/80 tumour cells can metabolise AQ4N under hypoxic conditions but that this ability is lost in isolated cells within 24 h (unpublished data).
Several advantages result from the differences in the chemical properties of AQ4N and its reduction product AQ4. Firstly, the stability of AQ4 and its high binding affinity for DNA allows for a long residence time in the cells in which it is formed. The demonstrated long interval of interaction between drug and radiation ( Figure 5) In previous studies we have derived a dose enhancement ratio (DER) to assess bioreductive activation of drugs in vivo. This was measured by assessing the enhancement of the anti-tumour effect of the drug when the tumour was rendered hypoxic in vivo using hypobaric hypoxia (McAleer et al., 1992) . When AQ4N was tested, it showed limited antitumour effect at normal levels of oxygenation. With hypoxia a significantly lower dose of AQ4N was required to give the same anti-tumour effect with a DER of 5.1 (Figure 3 ), suggesting that AQ4N may be toxic to hypoxic cells in vivo through the production of AQ4. Although the DER for AQ4N was less than that obtained previously with SR 4233 and RSU 1069 (Table I) , AQ4N showed significant bioreductive potential as measured by this test system.
Ideally a bioreductive drug should show selective toxicity to the treatment-resistant hypoxic cells of tumours, without toxicity to normally oxygenated tissues. This should result in sparing of normal tissues and yield a high therapeutic ratio. In mice kept at normal levels of oxygenation AQ4N showed only a minimal increase in systemic toxicity (as measured by weight loss) with doses that showed measurable anti-tumour effect. In particular, AQ4N showed almost no toxicity at doses that gave effective enhancement of radiation induced cell kill. In addition, systemic toxicity was not enhanced by hypoxia at doses up to 50 mg kg-', although hypoxia did potentiate systemic toxicity at higher doses of AQ4N. This suggests that normal tissues in these mice could metabolise the drug only when oxygen levels were artificially reduced.
The striking toxicity of SR 4233 in oxic mice at doses approaching the maximum tolerated dose suggest that sufficient metabolism of SR 4233 occurred systemically under conditions of normal oxygenation. This effect was further enhanced by hypoxia. Minchinton obtained milar results for SR 4233 when it was administered in combination with normobaric hypoxia (10% oxygen). In contrast, RSU 1069 showed significnt toxicity only in hypoxc mice. The recent study by Koch (1993) provides an explanation for the higher systemic toxicity of SR 4233 shown both in our studies and that of Minchinton and Brown (1992) .
Clinical use of bioreductive drugs will require their combination with an agent toxic to well-oxygenated cells. Investigation of AQ4N with radiation showed it to be a very efficent dose-spanng agent, giving a substantal reduction (50%) in radiation dose to give the same anti-tumour effect ( Figure 5 ). Several similar studies have shown additive or supra-additive interactions when bioreductive drugs are combined with radiation treatments (Brown and lemmon, 1991; Cole et a., 1991; Grau and Overgaard, 1991 immediately after irradiation it may be metabolised to produce AQ4 in hypoxic cells and prevent them from repopulating the tumour. If this time interval is prolonged regeneration of the oxic fraction will occur from the residual, mainly hypoxic, cells. Thus the number of cells sensitive to AQ4N will be reduced. Moore (1988) used split dose data and found that the oxic fraction was regenerated by about 3 days. This would explain why AQ4N retained its activity when administered up to 48 h after irradiation as the tumour would still have a large number of sensitive hypoxic cells.
Clinical radiotherapy is normally given as a fractionated regimen. When AQ4N was administered with fractionated radiation the extent of anti-tumour toxicity was similar to that obtained with the single-dose experiments. The most effective outcome was obtained when the AQ4N was also split into five equal doses given daily with radiation. This suggests that on each day of aministration a small additional fraction of acutely hypoxic cells was killed, increasng the anti-tumour effect. The phenomenon of acute hypoxia has been described previously by Trotter et al. (1990) . A significantly increased anti-tumour effect was obtained with a single dose of drug combined with five fractions of radiation, although this was not as effective as that found when both modalities were administered as fractionated regimens. The results suggest that AQ4N may have considerable potential for combination with fractionated radiation schedules at drug doses that should not cause systemic toxicity. Further studies are planned to examine dosing schedules for both modalities.
In conclusion, AQ4N is a novel drug which shows bioreductive activation nvivo. We have shown AQ4N to have an additive anti-tumour effect when combined with radiation, even when there is a long separation time between administation of the two modalities. Our studies have highlighted four major properties of AQ4N which might be exploited in clinical studies. (1) When given in combination with radiation AQ4N allows a significant reduction in radiation dose for an equivalent anti-tumour effect. (2) AQ4N has minimal toxicity at doses effective in combined modality expeLimes, suting that the radiation sparing may be achieved without advese sstemi toxicity. (3) The dosesparing effect can be elicited even if AQ4N is administed several hours (even days) before the radiation. This scheduling should allow sufficient time for the prodrug to be eliminated from normal tisues before irTadiation, thus reducing the risk of hand, drug-related, normal tissue toxicity in the radiation fiel (4) An equally effective interaction is obWained when AQ4N is combined with fractionated radiation, suggesting potential for AQ4N to be combined with clinical radiotherapy regimens.
